In the Journals

CABERNET trial: Epimacular brachytherapy inferior to ranibizumab monotherapy

Ranibizumab injections alone yielded better anatomic outcomes than epimacular brachytherapy combined with as-needed doses of ranibizumab in eyes with age-related macular degeneration, according to a study.

The CNV secondary to AMD treated with BEta RadiatioN Epiretinal Therapy (CABERNET) trial, a multicenter randomized study, included 227 patients who underwent epimacular brachytherapy (EMBT), two monthly intravitreal injections of 0.5 mg Lucentis (ranibizumab, Genentech) and subsequent as-needed (PRN) doses of ranibizumab.

A control group of 119 patients received three mandated monthly ranibizumab injections followed by mandated quarterly and PRN injections.

Investigators used fundus fluorescein angiography (FA) and optical coherence tomography (OCT) to assess lesion size and choroidal neovascularization (CNV) for 24 months.

Total FA lesion size increased a mean of 1.9 mm2 in the EMBT group and decreased 3 mm2 in the control group; the between-group difference was statistically significant (P < .0001).

Total CNV size increased 0.4 mm2 in the EMBT group and decreased 4.7 mm2 in the control group (P < .0001).

Mean OCT centerpoint thickness decreased by 144 μm in the EMBT group and 221 μm in the control group; the between-group difference was statistically significant (P = .003).

Disclosure: NeoVista Inc. participated in study design and data collection, management, analysis and interpretation, and in preparation, review and approval of the study manuscript. See the study for a full list of all authors’ relevant financial disclosures.

Ranibizumab injections alone yielded better anatomic outcomes than epimacular brachytherapy combined with as-needed doses of ranibizumab in eyes with age-related macular degeneration, according to a study.

The CNV secondary to AMD treated with BEta RadiatioN Epiretinal Therapy (CABERNET) trial, a multicenter randomized study, included 227 patients who underwent epimacular brachytherapy (EMBT), two monthly intravitreal injections of 0.5 mg Lucentis (ranibizumab, Genentech) and subsequent as-needed (PRN) doses of ranibizumab.

A control group of 119 patients received three mandated monthly ranibizumab injections followed by mandated quarterly and PRN injections.

Investigators used fundus fluorescein angiography (FA) and optical coherence tomography (OCT) to assess lesion size and choroidal neovascularization (CNV) for 24 months.

Total FA lesion size increased a mean of 1.9 mm2 in the EMBT group and decreased 3 mm2 in the control group; the between-group difference was statistically significant (P < .0001).

Total CNV size increased 0.4 mm2 in the EMBT group and decreased 4.7 mm2 in the control group (P < .0001).

Mean OCT centerpoint thickness decreased by 144 μm in the EMBT group and 221 μm in the control group; the between-group difference was statistically significant (P = .003).

Disclosure: NeoVista Inc. participated in study design and data collection, management, analysis and interpretation, and in preparation, review and approval of the study manuscript. See the study for a full list of all authors’ relevant financial disclosures.